Effects of Ezetimibe combined with Atorvastatin on serum ox-LDL,sdLDL-C and prognosis in elderly patients after PCI for acute myocardial infarction

WANG Gang; WANG Yan; ZHANG Hua

doi:10.13431/j.cnki.immunol.j.20260005

Abstract：Objective To investigate the effects of Ezetimibe combined with Atorvastatin on serum oxidized low-density lipoprotein(ox-LDL),small dense low-density lipoprotein cholesterol(sdLDL-C),and prognosis in elderly patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods A total of 86 elderly patients with AMI who received PCI from January to December 2022 were selected as study subjects.They were divided into the combination group and the control group according to random number table method,with 43 patients in each group.Both groups were given conventional PCI.The control group was supplemented with oral Atorvastatin Calcium(20 mg)once a day,and the combination group was supplemented with oral Ezetimibe(10 mg)once a day on the basis of the control group.All patients were treated for 1 month.Serum levels of ox-LDL,sdLDL-C,and inflammatory factors[monocyte chemoattractant protein-1(MCP-1),interleukin-6(IL-6)],and tumor necrosis factor-α(TNF-α)]in both groups were observed before and after treatment.Changes in left ventricular ejection fraction(LVEF)and left ventricular end-diastolic dimension(LVEDD)before and after treatment were compared between the two groups.Major adverse cardiovascular events(MACE)that occurred within 6 months after treatment and adverse reactions during treatment were recorded.Results After treatment,the serum levels of ox-LDL,sdLDL-C,MCP-1,IL-6,and TNF-α in both groups decreased,and the levels were lower in the combination group than in the control group(P<0.05,P<0.01).After treatment,serum levels of MCP-1,IL-6,and TNF-α decreased in both groups compared with those before treatment,which were lower in the combination group than in the control group(P<0.05,P<0.01).After treatment,LVEF increased,while LVEDD decreased in both groups.Moreover,the combination group had higher LVEF and lower LVEDD than the control group(P<0.05,P<0.01).The incidence of MACE in the combination group[4.65%(2/43)]was lower than that in the control group[20.93%(9/43)],showing significant difference(P<0.05),and the incidence of adverse reactions during treatment was comparable between the two groups(P>0.05).Conclusion Ezetimibe combined with Atorvastatin Calcium can more effectively reduce serum ox-LDL and sdLDL-C levels,alleviate inflammation,improve cardiac function,and lower the risk of short-term MACE in elderly patients with AMI after PCI,with controllable adverse reactions.